|
Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors. |
|
|
Stock and Other Ownership Interests - Pfizer |
Consulting or Advisory Role - Merck |
Research Funding - Jubilant DraxImage (Inst); Merck (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - GlaxoSmithKline |
|
|
Consulting or Advisory Role - Lilly; Roche/Genentech |
Research Funding - Genentech/Roche (Inst); Novartis (Inst); Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Axiom Healthcare Strategies; Bayer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - GE Healthcare; Johnson & Johnson; Teva; Varian Medical Systems |
Consulting or Advisory Role - Ventana Medical Systems |
Research Funding - Bayer (Inst); Ignyta (Inst); Lilly (Inst); Merck (Inst); Roche (Inst) |
Patents, Royalties, Other Intellectual Property - Patent for non-invasive methods of leukemia cell detection with MRI/MRS - Patent No. 8894975 |
|
|
Honoraria - Jazz Pharmaceuticals |
Consulting or Advisory Role - Jazz Pharmaceuticals |
|
|
Consulting or Advisory Role - Bayer |
|
|
Consulting or Advisory Role - EUSA Pharma |
Research Funding - Celgene |
Travel, Accommodations, Expenses - EUSA Pharma |
|
|
Research Funding - CancerFree Kids; CancerFree Kids; CancerFree Kids; CancerFree Kids; CancerFree Kids; CancerFree Kids; CancerFree Kids; CancerFree Kids |
Other Relationship - Novartis; Novartis; Novartis; Novartis |
|
|
No Relationships to Disclose |
|
|
Research Funding - Exelixis; Novartis; Roche |
|
|
Employment - Roche Canada |
|
|
|
Stock and Other Ownership Interests - Roche |
Consulting or Advisory Role - Genentech/Roche |
|
|
|
|
|
|
|
|
Research Funding - Genentech (Inst); Kazia Therapeutics (Inst) |
|
|
Research Funding - Ignyta (Inst); Novartis (Inst) |
Other Relationship - Helsinn Therapeutics |